What Can I Take to Lower My A1C? Meds and Supplements

Prescription medications remain the most reliable way to bring down your A1C, with metformin still the usual starting point and newer drugs like GLP-1 receptor agonists producing some of the largest drops seen in clinical trials. A handful of supplements, particularly berberine and magnesium, show real but more modest effects in studies, while others that get heavy marketing have weaker or contradictory evidence behind them. The gap between what a prescription drug can do and what a supplement can do is substantial, and understanding both sides helps you make decisions that actually move the needle.

What A1C Actually Reflects

Your A1C percentage represents a weighted average of your blood sugar over the previous two to three months, not a simple snapshot of where you are today. Red blood cells live about 120 days, and glucose sticks to the hemoglobin inside them over their lifespan. But the “weighted” part matters: blood sugar levels from the most recent 30 days contribute far more to your A1C reading than levels from 90 to 120 days ago.¹ That means a meaningful change in your daily glucose can shift your A1C in weeks, not the full four months some people assume.² This is encouraging if you are starting a new medication or supplement, because you do not have to wait an entire red-blood-cell cycle to see the number move.

Metformin as the Starting Point

Metformin has been the first-line drug for type 2 diabetes for decades, and for good reason. It typically lowers A1C by about one percentage point when used alone, which is on par with most other oral diabetes drugs.³ Its main trick is reducing the amount of glucose your liver produces between meals, though researchers have found it also works through effects in the gut and through several molecular pathways that are still being sorted out.⁴ It does not cause low blood sugar on its own, it is cheap and generic, and it has a long safety record. The most common complaints are gastrointestinal: nausea, diarrhea, and stomach cramps, especially in the first few weeks. Extended-release versions tend to be easier on the gut.

Where metformin falls short is in people who need a larger A1C reduction than one point, or who cannot tolerate the side effects. That is when doctors layer on additional medications.

GLP-1 Receptor Agonists and Dual Agonists

If you have spent any time online reading about diabetes or weight loss, you have heard of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). These injectable drugs belong to a class that mimics gut hormones involved in blood sugar regulation, and they produce some of the largest A1C reductions of any available therapy. In a head-to-head trial, semaglutide lowered A1C by about 1.9 percentage points, while tirzepatide at its highest dose lowered it by roughly 2.3 points.⁵ Tirzepatide was superior to semaglutide at all three tested doses in that trial. A systematic review and meta-analysis confirmed that tirzepatide brought A1C and body weight significantly lower than other comparators without a meaningful increase in dangerous low-blood-sugar episodes.⁶

Real-world data backs up the clinical trials. In a large observational study, people new to injectable therapy who started tirzepatide saw an average A1C drop of 1.3 points, compared with 0.9 points for semaglutide starters. Weight loss was also greater with tirzepatide: about 10 kg versus 6 kg in treatment-naive patients.⁷ Nausea and other GI symptoms are the most common side effects with both drugs, though they tend to improve after the first few weeks as the dose ramps up.

SGLT2 Inhibitors

SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, work by a completely different mechanism from the drugs above. They block a transporter in the kidneys that normally reabsorbs about 90% of filtered glucose back into the blood.⁸ By shutting that transporter down, the drugs cause you to excrete excess glucose in your urine. The result is a modest A1C reduction of roughly half a point to just under one point, whether used alone or added to another drug.⁹

The A1C drop is smaller than what GLP-1 drugs deliver, but SGLT2 inhibitors come with side benefits that make them attractive for many patients. They also reduce weight and have shown cardiovascular and kidney-protective effects in large trials.¹⁰ The trade-off is a higher risk of genital yeast infections, because extra sugar in the urine creates a hospitable environment for fungal growth. Urinary tract infections are also reported more often, and in rare cases a serious condition called diabetic ketoacidosis can occur. A meta-analysis of glucose-lowering drugs found that SGLT2 inhibitors added to metformin offered the lowest odds of low blood sugar among all add-on classes.¹¹

DPP-4 Inhibitors Versus Sulfonylureas

Sulfonylureas (like glipizide and gliclazide) have been around for decades and work by pushing the pancreas to release more insulin. They lower A1C by about one percentage point, which is in the same ballpark as metformin.³ The downside is a real risk of low blood sugar and weight gain. A meta-analysis of randomized trials found that sulfonylureas carried about three times the odds of hypoglycemia compared with DPP-4 inhibitors.¹²

DPP-4 inhibitors (sitagliptin, linagliptin, and others) work by prolonging the activity of incretin hormones that stimulate insulin release only when blood sugar is elevated. Their A1C-lowering power is slightly weaker than sulfonylureas, but they cause much less hypoglycemia and a small amount of weight loss rather than weight gain. In a real-world matched-cohort study, patients starting a DPP-4 inhibitor saw a 0.6-point A1C drop compared with 0.4 points for those starting gliclazide over six months.¹³ For many people, the trade between a marginally smaller glucose reduction and far fewer episodes of dangerously low blood sugar tips firmly in favor of DPP-4 inhibitors, especially if they are on other drugs that already carry a hypoglycemia risk.

Berberine

Berberine is the supplement with the strongest clinical data for lowering A1C, and it is often compared to metformin in casual health circles. It is a plant-derived alkaloid found in goldenseal, Oregon grape, and several other botanicals. In a frequently cited trial of 116 people with type 2 diabetes, taking 1 gram of berberine per day for three months dropped A1C from 9.5% to 7.5% in a newly treated group and from 8.1% to 7.3% in a group that added berberine to existing therapy.¹⁴ Those are meaningful drops that rival what prescription oral drugs accomplish. Berberine activates some of the same molecular pathways as metformin, and it also lowers fasting glucose and triglycerides.¹⁵

The catch is that most berberine trials have been small and relatively short, and the large-scale, long-term safety data that prescription drugs must generate simply does not exist for berberine. GI side effects (diarrhea, constipation, bloating) are common. Because berberine can interact with drugs metabolized by certain liver enzymes, you should tell your doctor about it if you are on other medications, particularly statins or immunosuppressants.

Cinnamon

Cinnamon supplements are widely marketed for blood sugar control, and there is a kernel of truth buried under quite a bit of hype. A randomized controlled trial using Ceylon cinnamon extract showed a modest reduction in fasting blood sugar, particularly in participants who already had type 2 diabetes.¹⁶ The effect was statistically detectable but small enough that it would not replace any medication on its own. Many studies on cinnamon have used inconsistent doses, different species, and short durations, making the overall evidence base messy.

Which species you use matters for safety reasons. Most cinnamon in grocery stores and cheap supplements is cassia cinnamon, which contains high levels of coumarin, a compound that can harm the liver at large daily doses. Cassia cinnamon can contain coumarin levels as high as 10%, while Ceylon (or “true”) cinnamon contains only trace amounts.¹⁷ If you choose to try cinnamon for blood sugar, using Ceylon cinnamon and keeping the dose moderate reduces the liver toxicity concern.

Magnesium

Many people with type 2 diabetes run low on magnesium, and correcting that deficiency appears to improve insulin sensitivity and glucose control. In a controlled trial, giving 250 mg of elemental magnesium daily for three months lowered A1C from about 8.3% to 8.0% in the supplemented group, while the control group stayed higher. Insulin resistance, measured by HOMA-IR, also improved significantly in the magnesium group.¹⁸ Another double-blind trial found that magnesium chloride supplementation restored serum magnesium levels and improved both fasting glucose and A1C compared with placebo, specifically in patients whose magnesium was low at baseline.¹⁹

The likely mechanism is that intracellular magnesium plays a role in insulin signaling. When magnesium levels drop, the enzymes involved in insulin’s action become less efficient, worsening insulin resistance.²⁰ The benefit seems most pronounced in people who are actually deficient. If your magnesium levels are already normal, supplementing may do little for your A1C.

Alpha-Lipoic Acid

Alpha-lipoic acid (ALA) is an antioxidant naturally produced in the body in small amounts and available as a supplement. It has a modest effect on glucose markers. A systematic review and meta-analysis pooling multiple trials found that ALA supplementation lowered A1C by about a third of a percentage point and reduced fasting blood sugar as well. It also reduced markers of inflammation including TNF-alpha, IL-6, and C-reactive protein.²¹ That A1C reduction is real but small, roughly in the same territory as what cinnamon or chromium might deliver. ALA is more commonly recommended for diabetic nerve pain (peripheral neuropathy), where the evidence is somewhat stronger, and any glucose benefit is essentially a bonus.²²

Chromium and Vitamin D

Chromium picolinate is one of the most widely sold diabetes supplements, yet the evidence is genuinely mixed. One randomized trial in patients with type 2 diabetes found that chromium supplementation lowered A1C significantly more than the control group.²³ But a separate randomized trial testing both 500 and 1,000 mcg doses found no change in A1C, fasting glucose, insulin levels, or insulin resistance after six months compared with placebo.²⁴ The positive trials tend to be in people with poor baseline glucose control, while trials in people with milder elevations or prediabetes often show nothing. If you are already on effective medication and eating reasonably well, chromium is unlikely to add much.

Vitamin D has generated more consistent signals. A network meta-analysis of 178 randomized trials comparing different nutritional supplements head to head found that after excluding low-quality studies and restricting to trials lasting 12 weeks or more, vitamin D was the only supplement that significantly reduced A1C, fasting blood sugar, and insulin resistance across all three markers.²⁵ The effect was modest, and the certainty of evidence was still rated low, but it stood out relative to other supplements tested. Vitamin D deficiency is common in people with diabetes, so similar to magnesium, correcting an existing deficiency may matter more than supplementing from a normal baseline.

Probiotics and Fiber

The gut microbiome has become a hot topic in diabetes research, and probiotics and prebiotics (fibers that feed beneficial bacteria) are increasingly studied as supplemental therapies. The rationale is that gut bacteria influence incretin hormones, the same hormones targeted by GLP-1 drugs, and that restoring healthier microbial balance could reduce intestinal inflammation and improve insulin sensitivity.²⁶ Most trials so far are small and use wildly different bacterial strains and doses, so there is no consensus on which probiotic, at what dose, actually lowers A1C in a reproducible way. Fiber supplementation on its own (psyllium, inulin, or resistant starch) tends to help with post-meal glucose spikes, though the A1C effect is small. This area is worth watching but not yet worth building a treatment plan around.

Why Supplement Quality Is a Bigger Problem Than Most People Realize

Dietary supplements in most countries, including the United States, do not go through the same pre-market approval process that prescription drugs do. This creates a quality problem that goes well beyond “you might not get what the label says.” A safety screening of herbal antidiabetic supplements found that a third of samples had a combined hazard index for toxic metals above the acceptable threshold, and the majority of samples exceeded carcinogenic risk limits for lead, chromium, cadmium, or nickel.²⁷ A separate analysis of botanical supplements on the U.S. market found substantial deviations from the biomarker amounts advertised on labels, with one product containing an undisclosed synthetic compound, and all tested capsule products containing trace amounts of arsenic, cobalt, and lead.²⁸

If you do take supplements, choosing products tested by a third-party lab (look for USP, NSF, or ConsumerLab seals) significantly reduces the risk of contamination and mislabeling. This does not guarantee the supplement will work, but it at least means the capsule contains what it claims to contain and is not laced with unsafe levels of heavy metals.

The Cost and Adherence Problem With Newer Drugs

GLP-1 receptor agonists and SGLT2 inhibitors deliver impressive A1C reductions in trials, but those benefits evaporate if you cannot afford to stay on the drug. High out-of-pocket costs remain one of the biggest real-world barriers. Among Medicare beneficiaries, higher personal spending on SGLT2 inhibitors was linked to measurably lower adherence, with each additional $100 in out-of-pocket cost associated with reduced medication-taking behavior.²⁹ For GLP-1 receptor agonists, the picture is starker: in unsubsidized settings, persistence on therapy can drop below 10%.³⁰

This financial reality is part of why older, cheaper drugs like metformin and sulfonylureas remain so widely used around the world. And it is part of why some people turn to supplements like berberine, which costs a fraction of a branded injectable. The science favors prescription medications, especially the newer ones, but science only helps if you can actually take the medication consistently. Having an honest conversation with your doctor about cost and coverage is just as important as discussing which molecule works best in a trial setting.

When A1C Can Mislead You

A1C is the standard metric for long-term glucose control, but it has blind spots. Any condition that changes how long red blood cells survive will skew the number. Chronic anemia, major blood loss, hemolysis (where red blood cells break apart faster than normal), kidney disease, pregnancy, and even smoking can all push A1C readings artificially high or low.³¹ Certain hemoglobin variants, common in people of African, Mediterranean, or Southeast Asian descent, can also interfere with some A1C assays. If your A1C does not seem to match how your daily glucose readings look, ask your doctor whether one of these factors could be at play. Alternatives like fructosamine or a continuous glucose monitor’s time-in-range metric can fill in the picture when A1C alone is not reliable.

Combining Exercise With Medication

Exercise on its own improves insulin sensitivity and lowers blood sugar, but combining it with medication tends to produce additive effects. A study of patients with mild type 2 diabetes found that pairing regular exercise with the glucose-lowering drug acarbose produced greater reductions in fasting glucose, A1C, lipids, and blood pressure than either approach alone, while improvements in fitness and body composition were similar to exercise by itself.³² The same principle applies broadly: whatever medication or supplement you are taking, consistent physical activity tends to lower A1C further than either effort alone. You do not need extreme exercise programs. Walking briskly after meals, resistance training a few times a week, or any movement that makes your muscles use more glucose will contribute.

Emerging Approaches

The pipeline for new glucose-lowering drugs continues to expand. Imeglimin is a first-in-class oral agent that works through a different mechanism than existing drugs, reducing liver glucose output, boosting muscle glucose uptake, and improving how the pancreas secretes insulin in response to a meal. In a phase II trial, adding imeglimin to metformin was well-tolerated and improved glucose control beyond what metformin alone achieved.³³ It is already approved in Japan and under evaluation elsewhere. Other areas of active research include oral GLP-1 drugs (eliminating the need for injections), combination pills that merge two mechanisms into a single tablet, and glucose-responsive “smart” insulins that activate only when blood sugar rises. For now, these remain either early-stage or recently launched, but they suggest the toolkit for managing A1C is only going to get broader over the coming years.